
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
Key takeaways The expanded FDA approval of Farapulse introduces a non-thermal ablation option for persistent AF, potentially shifting treatment pathways and protocol design. ADVANTAGE AF data reinforce the importance of operator experience in outcomes, …